Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997319 · ClinicalTrials.gov registry record
Shift Work, Heredity, Insulin, and Food Timing Study
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 365
- Enrollment target
NCT02997319: Completed study, sponsored by Massachusetts General Hospital.
NCT02997319 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 365 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02997319 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 365 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether night time eating that coincides with elevated endogenous melatonin impairs glucose tolerance, particularly in carriers of the MTNR1B risk allele.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2021-05-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02997319
The ClinicalTrials.gov registry entry for NCT02997319 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02997319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02997319 about?
NCT02997319 is a clinical study titled "Shift Work, Heredity, Insulin, and Food Timing Study". The purpose of this study is to determine whether night time eating that coincides with elevated endogenous melatonin impairs glucose tolerance, particularly in carriers of the MTNR1B risk allele.
What is the current status of trial NCT02997319?
This trial is currently completed. The enrollment target is 365 participants. The study started on 2017-02-24. Estimated completion is 2021-05-08.
Who is sponsoring clinical trial NCT02997319?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.